Physician profile
Danielle E Chellappoo
NPI 1831351642
$4,106.53
in general payments reported to CMS, 2019-2025
31 companies · $77.49 in 2025
The $77.49 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,309 · 2022: $575 · 2023: $909 · 2024: $236 · 2025: $77.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.26 |
| Education | $264.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $846.90 | 2021-2023 | |
| Glaxosmithkline, LLC. | $616.55 | 2021-2025 | Ojjaara |
| Amgen INC. | $301.03 | 2021-2023 | Lumakras |
| Novartis Pharmaceuticals Corporation | $300.40 | 2021-2024 | |
| Asd Specialty Healthcare, LLC | $213.28 | 2021-2023 | |
| Seagen INC. | $211.36 | 2021-2023 | Tivdak |
| Janssen Biotech, INC. | $208.32 | 2021-2025 | Rybrevant, Carvykti, Imbruvica |
| Sanofi-Aventis U.S. LLC | $176.65 | 2021-2023 | |
| Incyte Corporation | $133.16 | 2022-2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $124.73 | 2022-2023 | Ninlaro |
| Astrazeneca Pharmaceuticals Lp | $118.89 | 2023 | Calquence, Tagrisso |
| Abbvie INC. | $104.34 | 2021-2023 | |
| Pfizer INC. | $97.95 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $76.33 | 2023 | Monoferric |
| Rigel Pharmaceuticals, INC. | $64.31 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $57.99 | 2021-2022 | |
| Mirati Therapeutics, INC. | $55.03 | 2023 | Krazati |
| Astellas Pharma US INC | $53.32 | 2021 | |
| Merck Sharp & Dohme LLC | $48.62 | 2021-2023 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $33.49 | 2022-2023 | Opdivo |
| Lilly USA, LLC | $33.20 | 2021-2023 | Verzenio, Retevmo, Jaypirca |
| Eisai INC. | $32.22 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $30.92 | 2022 | |
| Coherus Oncology, INC. | $28.91 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $27.37 | 2021 | |
| Adaptive Biotechnologies Corporation | $24.15 | 2022 | |
| Taiho Oncology, INC. | $21.23 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.31 | 2023 | |
| Gilead Sciences, INC. | $16.61 | 2021 | |
| Tactile Systems Technology INC | $15.18 | 2021 | |
| Genentech USA, INC. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Chellappoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.